【摘要】 目的观察多西紫杉醇联合卡培他滨作为一线方案治疗乳腺癌肝转移的疗效及安全性。方法42例乳腺癌肝转移患者采用多西紫杉醇75mg/m~2,静脉滴注,第1天,卡培他滨950mg/m~2,2次/d,口服,第1天至第14天;每21天为1个周期,治疗至少2个周期评价疗效。结果完全缓解(CR)4例,部分缓解(PR)19例,稳定(SD)9例,进展(PD)6例,总有效率为54.76%(23/42),临床获益(CBR)率64.28%,中位疾病进展时间(TIP)10.1个月,中位生存时间17.5个月。常见不良反应为白细胞和中性粒细胞减少(76.1%和71.4%)、手足综合征(45.2%)和恶心、呕吐(52.3%),多数为Ⅰ～Ⅱ度。结论多西紫杉醇联合卡培他滨作为一线方案治疗乳腺癌肝转移疗效较高,安全性较好,不良反应可以耐受。更多还原

【Abstract】 Objective To determine the efficacy and tolerability of docetaxel plus capecitabine as first-line treatment for breast cancer with liver metastases(BCLM).Methods Forty-two patients with BCLM received oral capecitabine 1900 mg/m~2/d(950 mg/m~2 twice daily)on days 1 through 14 and intravenous infu- sion of Docetaxel at 75 mg/m~2 on day 1 of each 21-day treatment cycle.Patients were evaluated for the re- sponse after two cycles.Results Among these 42 patients,the overall response rate was 54.76% with 4 CR, 19 PR, 9 SD and 6 PD.The clinical benefit rate was 64.28% and the median overall survival time was 17.5 months.The most common treatment-related adverse events were leukopenia(76.1%),neutropenia(71.4%), hand-foot syndrome(45.2%),nausea and vomiting(52.3%),which were mainly gradeⅠ～Ⅱ.Conclusion The combination of docetaxel plus capocitabine is a highly active and generally well-tolerated regimen for first-line treatment of BCLM.更多还原